MeiraGTx Holdings plc is a clinical-stage company developing genetic medicine treatments using adeno-associated virus vectors and other approaches targeting conditions in ophthalmology, neurology, and other therapeutic areas. The company's pipeline includes programs in various stages of development, from early-stage research through Phase 2 clinical trials, alongside technology platforms for peptide delivery and cell therapies. MeiraGTx has partnerships with major pharmaceutical companies including Johnson & Johnson for inherited retinal diseases and Hologen for neurological conditions and metabolic disorders.

entry readiness 29 · NOT READY · exit proximity 0

Value area 8.68–12.85 · 23% of 120d volume overhead · moderate overhead